Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical ...

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit ...

Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine. New Drug Application (NDA) Submission Expected in the ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...

Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...

Revalesio updates new analyses from phase 2 RESCUE clinical study of RNS60 in patients with acute ischemic stroke: Tacoma, Washington Friday, February 7, 2025, 18:00 Hrs [IST] Rev ...

MIND was a prospective, open-label trial that enrolled adults up to 80 years old with moderate-large (20-80 mL) ...

treatment with REC-994 400 mg showed promising signals in both MRI-based lesion volume reduction and functional outcome as ...

Cerebral cavernous malformation (CCM) patients treated with oral drug, REC-994, showed reduction in total cerebral and brainstem lesion volume.

Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison to placebo, treatment with REC-994 400 mg showed promi ...

University of Cincinnati experts will present research at the International Stroke Conference 2025 in Los Angeles.

The modified Rankin Scale (mRS) is a commonly used functional outcome assessment in stroke clinical trials and has become an essential metric for stroke research. However, the mRS is not routinely ...